Basic and translational research

Objective Systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are related chronic autoimmune diseases of complex aetiology in which the interferon (IFN) pathway plays a key role. Recent studies have reported an association between IRF7 and SLE which confers a risk to autoantibody production. A study was undertaken to investigate whether the IRF7 genomic region is also involved in susceptibility to SSc and the main clinical features. Methods Two case-control sets of Caucasian origin from the USA and Spain, comprising a total of 2316 cases of SSc and 2347 healthy controls, were included in the study. Five single nucleotide polymorphisms (SNPs) in the PHRF1-IRF7-CDHR5 locus were genotyped using TaqMan allelic discrimination technology. A meta-analysis was performed to test the overall effect of these genetic variants on SSc. Results Four out of five analysed SNPs were significantly associated with the presence of anticentromere autoantibodies (ACA) in the patients with SSc in the combined analysis (rs1131665: pFDR=6.14 × 10−4, OR=0.78; rs4963128: pFDR=6.14 × 10−4, OR=0.79; rs702966: pFDR=3.83 × 10−3, OR=0.82; and rs2246614: pFDR=3.83 × 10−3, OR=0.83). Significant p values were also obtained when the disease was tested globally; however, the statistical significance was lost when the ACA-positive patients were excluded from the study, suggesting that these associations rely on ACA positivity. Conditional logistic regression and allelic combination analyses suggested that the functional IRF7 SNP rs1131665 is the most likely causal variant. Conclusions The results show that variation in the IRF7 genomic region is associated with the presence of ACA in patients with SSc, supporting other evidence that this locus represents a common risk factor for autoantibody production in autoimmune diseases.

[1]  B. Tsao,et al.  Recent insights into the genetic basis of systemic lupus erythematosus , 2012, Annals of the rheumatic diseases.

[2]  G. Barber,et al.  IRF7: activation, regulation, modification and function , 2011, Genes and Immunity.

[3]  Annette Lee,et al.  Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody Production , 2011, PLoS genetics.

[4]  F. Arnett,et al.  Association of a functional IRF7 variant with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[5]  Javier Martín,et al.  The Genetics of Scleroderma , 2011, Current rheumatology reports.

[6]  M. Mayes,et al.  Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts , 2011, Arthritis research & therapy.

[7]  M. Mayes,et al.  Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. , 2010, Journal of autoimmunity.

[8]  Annette Lee,et al.  Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus , 2010, Nature Genetics.

[9]  S. Sozzani,et al.  Type I interferons in systemic autoimmunity , 2010, Autoimmunity.

[10]  J. Reveille,et al.  The genetics of scleroderma (systemic sclerosis) , 2010, Current opinion in rheumatology.

[11]  M. Jolly,et al.  Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. , 2010, Arthritis and rheumatism.

[12]  V. Pascual,et al.  Systemic sclerosis and lupus: points in an interferon-mediated continuum. , 2010, Arthritis and rheumatism.

[13]  M. Koenig,et al.  Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. , 2008, Autoimmunity reviews.

[14]  Sarah A. Pendergrass,et al.  Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PloS one.

[15]  D. Pritchard,et al.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. , 2008, Arthritis and rheumatism.

[16]  M. Crow Collaboration, genetic associations, and lupus erythematosus. , 2008, The New England journal of medicine.

[17]  Marta E Alarcón-Riquelme,et al.  Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci , 2008, Nature Genetics.

[18]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[19]  R. Lafyatis,et al.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. , 2007, Arthritis and rheumatism.

[20]  D. Furst,et al.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[21]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[22]  M. Mayes,et al.  Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. , 2006, Arthritis and rheumatism.

[23]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[24]  Hideo Negishi,et al.  IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.

[25]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[26]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[27]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Yagi,et al.  Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. , 2000, Genes & development.

[29]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[30]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[31]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[32]  T. Krieg,et al.  [Pathogenesis of systemic sclerosis]. , 2007, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .